Wine Making

UV applied continues Global Ex

  • AFRIMS to installAirocide® technology to protect visitors and staff
  • AFRIMS is a biomedical research center of the Walter Reed Army Institute of Research of the United States Army
  • MOUNT VERNON, NY / ACCESSWIRE / December 1, 2021 / Applied UV, Inc. (NASDAQ: AUVI) (“Applied UV” or the “Company”), a pathogen removal technology company that applies the power of short-range ultraviolet light (“UVC”) to surfaces and catalytic bioconversion technology for air purification to destroy pathogens safely, completely and automatically, announced that its exclusive distribution partner in Thailand will install Airocide® units at the Armed Forces Research Institute of Medical Sciences (“AFRIMS”), Bangkok, Thailand, to help create safer and cleaner environments for visitors and staff. AFRIMS is a biomedical research center of the Walter Reed Army Institute of Research (“WRAIR”) of the United States Army. AFRIMS, whose mission has resulted in groundbreaking research in military medicine in countries of Southeast Asia and the Indian subcontinent, has mainly focused on diseases related to infectious pathogens.

    AFRIMS has a dual Royal Thai Army and US Army Command, with the US component being a special foreign activity of WRAIR in Washington, DC. Since 1893, WRAIR has been a leader in addressing significant threats to soldier readiness and lethality, such as illness and injury in combat. WRAIR’s extensive research capabilities in its Washington, DC area and expeditionary laboratories work together to provide soldiers with the best medical protection and support possible before, during and after deployment by addressing long-standing threats. and emerging. Although WRAIR’s research focuses on the health of soldiers, its products have important civilian applications, saving countless lives around the world.

    With the ongoing fight against COVID-19 and the recent global emergence of the new Omicron strain, AFRIMS is installing Airocide® systems to control airborne diseases and protect critical areas of the facility. The installation of the Airocide GCS series units in the research center demonstrates the commitment of the Thai medical community to research and provide the best air purification and disinfection technology to protect their employees.

    Armed with one of the only Class II medical devices listed by the FDA clinically proven to kill COVID 19, Applied UV continues to improve relationships with its distributors across Southeast Asia and around the world to meet the demand for its air and surface infection control. some products. The installation in this leading military research center, coupled with other global facilities (JetBlue Park, Boston Red Sox, US Army Aberdeen Proving Grounds, Bangkok Metropolitan Administration Lat Krabang Hospital, Château de Versailles) further demonstrates the effectiveness and the safety of the patented Airocide air purification. platform by making these institutions trust the protection of their staff, consumers and facilities with our product.

    “The installation of our Airocide® units in such a prestigious biomedical facility represents another important step in our strategy to significantly expand our international commercial distribution capabilities and enter new markets,” said Max Munn, Founder and President of ‘Applied UV. “Our distributor in Thailand, Sithiporn Associates, is a leading distributor of scientific equipment in Thailand and the ASEAN region and has been excellent partners in bringing our innovative and clinically proven portfolio of disposal technologies to market. pathogens Hospitals and research centers are increasingly recognizing the advantages of installing Airocide® Systems in common areas to interrupt the transmission of airborne infectious agents and destroy these microbes quickly while protecting occupants of any harmful by-product. “

    Airocide® uses NASA’s optimized Photocatalytic Oxidation (“PCO”) technology in which air and all contaminants are drawn from the room to the Airocide® unit and channeled into the reaction chamber. UVC activates the proprietary photocatalyst built into the reaction chamber, starting the photocatalytic process. In the reaction chamber, hydroxyl radicals and superoxide ions are generated and oxidize every organic molecule that comes in contact. The reaction bed is designed to allow radicals bound to the surface near three hundred and sixty degrees of exposure for maximum probability of collisions with pathogens and other organic material. Millions of hydroxyl radicals converge, combining with carbon atoms in pathogens (airborne bacteria, molds, fungi, mycotoxins, viruses, allergens) and VOCs, converting organic matter into harmless vapor and a clean and clear air.

    Airocide system

    The Airocide® System, originally developed for NASA with assistance from the University of Wisconsin at Madison, is an airborne pathogen destruction technology that uses a patented combination of UVC and a proprietary photocatalyst. titanium dioxide base. Listed as an FDA Class II medical device, Airocide® technology is clinically proven and field tested to kill / eliminate / eliminate airborne pathogenic and non-pathogenic microorganisms, allergens, odors and harmful VOCs in a variety of applications and industries including healthcare, hospitality, grocery chains, wineries, commercial real estate, schools, dental offices, and homes. Airocide® air purifiers are available on www.airocide.com

    About applied UVs

    Applied UV is focused on the development and acquisition of infection control technologies in the healthcare, hospitality, commerce and municipal markets. The Company has two wholly owned subsidiaries – SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s Connected Platform for Data-Driven Disinfection ™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, completely and automatically, meeting the challenge of nosocomial infections (“HAI”) . Intended for use in high customer turnover facilities such as hospitals, hotels, commercial facilities and other public spaces, the company’s Lumicide ™ platform uses UVC LEDs in several patented designs for the control of infections in and around high traffic areas, including sinks and toilets, killing bacteria, viruses and other pathogens residing on hard surfaces near appliances. The company’s patented drain disinfection device, Lumicide Drain, is the only product on the market that tackles this critical, pathogen-intensive location. SteriLumen’s Airocide® products for air purification, developed for NASA and FDA, approved as Class II medical devices, use proprietary photocatalytic bioconversion technology that draws air into a reaction chamber that converts molds, microorganisms, dangerous pathogens, destructive VOCs and biological gases. into harmless water vapor without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, chain grocery stores, winemaking facilities, commercial real estate, schools, dental offices and homes.

    For more information about Applied UV, Inc. and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/; https://sterilumen.com/; and https://munnworks.com/.

    Forward-looking statements

    The information contained in this document may contain “forward-looking statements”. Forward-looking statements reflect the current view of future events. When used in this press release, the words “anticipate”, “believe”, “estimate”, “expect”, “the future”, “intend”, “plan” or the negative of these terms and similar expressions, to the extent that they relate to us or our management, identify forward-looking statements. These statements include, but are not limited to, statements in this press release regarding the opinion of the management of Applied UV with respect to its business strategy, future results of operations and prospects for liquidity and capital resources. . Forward-looking statements are based on the Company’s current expectations and assumptions regarding its business, economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The actual results of the Company may differ materially from those contemplated by forward-looking statements. They do not constitute statements of historical fact or guarantees of future performance. We therefore recommend that you do not rely on any of these forward-looking statements. Factors or events that could cause the actual results of the Company to differ may arise from time to time and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, activity levels, performance or achievements. Except as required by applicable law, including United States securities laws, the Company does not intend to update any forward-looking statements to conform such statements to actual results.

    Contact:

    Applied UV Investor Relations
    Kevin McGrath
    TraDigital IR
    + 1-646-418-7002
    [email protected]

    THE SOURCE: Applied UV, Inc.

    See the source version on accesswire.com:
    https://www.accesswire.com/675424/Applied-UV-Continues-Global-Expansion-with-AirocideR-Installations-in-Thailand-at-the-Acclaimed-Armed-Forces-Research-Institute-of-Medical- Sciences-AFRIMS


    Source link